A massive clonal expansion of activated CD8.sup.+ T-cells with increased frequency of HPV 16-specific CD8.sup.+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

The invention pertains to a mutant Bordetella OmpA polypeptide. A Bordetella comprising said mutant polypeptide has a high blebbing phenotype. Hence, the invention further pertains a method for producing OMVs, wherein the method comprises a step of culturing a population of Bordetella bacteria comprising a modified OmpA polypeptide, under conditions conductive for the production of OMVs. In addition, the invention pertains to OMVs produced by a Bordetella comprising a mutant OmpA polypeptide, and the use of such OMVs for the treatment and prevention of a Bordetella infection.

The invention pertains to a mutant Bordetella OmpA polypeptide. A Bordetella comprising said mutant polypeptide has a high blebbing phenotype. Hence, the invention further pertains a method for producing OMVs, wherein the method comprises a step of culturing a population of Bordetella bacteria comprising a modified OmpA polypeptide, under conditions conductive for the production of OMVs. In addition, the invention pertains to OMVs produced by a Bordetella comprising a mutant OmpA polypeptide, and the use of such OMVs for the treatment and prevention of a Bordetella infection.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordetella peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences, fusion proteins, a pool of 2 or more peptides, or polynucleotides that expression the amino acid sequences selected from those set forth in any one of Tables 1-20 (SEQ ID NOS: 1 to 2598). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordetella peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences, fusion proteins, a pool of 2 or more peptides, or polynucleotides that expression the amino acid sequences selected from those set forth in any one of Tables 1-20 (SEQ ID NOS: 1 to 2598). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

The present invention relates to processes for Bordetella fermentation and virulence factor production, especially PT production, for large scale manufacturing. More particularly, processes including a medium conditioning step carried out prior to inoculation.